New drug combo aims to beat stubborn bone infections
NCT ID NCT07435051
First seen Feb 28, 2026 · Last updated May 07, 2026 · Updated 8 times
Summary
This study tests whether adding bisphosphonates to the standard antibiotic vancomycin can better control chronic bone infections (osteomyelitis) that are hard to treat. About 280 adults with specific types of bone infection will receive either the combination or standard care. The main goal is to see if the infection is controlled within 6 months, shown by normal temperature, healed wounds, normal blood tests, and new bone growth on X-rays.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOMYELITIS (REFRACTORY) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
the Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.